The Utility of Urinary Titin to Diagnose and Predict the Prognosis of Acute Myocardial Infarction
Abstract
:1. Introduction
2. Results
2.1. Patient Characteristics
2.2. Urinary Titin Level between AMI and Non-AMI Patients
2.3. Level of Urinary Titin and Prognosis
3. Discussion
4. Materials and Methods
4.1. Study Design
4.2. Patient Selection Criteria
4.3. Urinary Titin
4.4. Troponin I, Creatine-Kinase, and Creatine Kinase-MB
4.5. Acute Myocardial Infarction
4.6. Clinical Outcomes
4.7. Statistical Analysis
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Bhatt, D.L.; Lopes, R.D.; Harrington, R.A. Diagnosis and Treatment of Acute Coronary Syndromes: A Review. JAMA 2022, 327, 662–675. [Google Scholar] [CrossRef] [PubMed]
- Cannon, C.P.; Gibson, C.M.; Lambrew, C.T.; Shoultz, D.A.; Levy, D.; French, W.J.; Gore, J.M.; Weaver, W.D.; Rogers, W.J.; Tiefenbrunn, A.J. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000, 283, 2941–2947. [Google Scholar] [CrossRef] [PubMed]
- Thygesen, K.; Alpert, J.S.; Jaffe, A.S.; Simoons, M.L.; Chaitman, B.R.; White, H.D.; Katus, H.A.; Apple, F.S.; Lindahl, B.; Morrow, D.A.; et al. Third universal definition of myocardial infarction. J. Am. Coll. Cardiol. 2012, 60, 1581–1598. [Google Scholar] [CrossRef] [PubMed]
- Apple, F.S.; Jesse, R.L.; Newby, L.K.; Wu, A.H.; Christenson, R.H. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical issues for biochemical markers of acute coronary syndromes. Circulation 2007, 115, e352–e355. [Google Scholar] [CrossRef] [PubMed]
- Odqvist, M.; Andersson, P.O.; Tygesen, H.; Eggers, K.M.; Holzmann, M.J. High-Sensitivity Troponins and Outcomes After Myocardial Infarction. J. Am. Coll. Cardiol. 2018, 71, 2616–2624. [Google Scholar] [CrossRef] [PubMed]
- Boeddinghaus, J.; Nestelberger, T.; Twerenbold, R.; Wildi, K.; Badertscher, P.; Cupa, J.; Bürge, T.; Mächler, P.; Corbière, S.; Grimm, K.; et al. Direct Comparison of 4 Very Early Rule-Out Strategies for Acute Myocardial Infarction Using High-Sensitivity Cardiac Troponin I. Circulation 2017, 135, 1597–1611. [Google Scholar] [CrossRef] [PubMed]
- Bandstein, N.; Ljung, R.; Johansson, M.; Holzmann, M.J. Undetectable high-sensitivity cardiac troponin T level in the emergency department and risk of myocardial infarction. J. Am. Coll. Cardiol. 2014, 63, 2569–2578. [Google Scholar] [CrossRef]
- Peacock, W.F.; Baumann, B.M.; Bruton, D.; Davis, T.E.; Handy, B.; Jones, C.W.; Hollander, J.E.; Limkakeng, A.T.; Mehrotra, A.; Than, M.; et al. Efficacy of High-Sensitivity Troponin T in Identifying Very-Low-Risk Patients With Possible Acute Coronary Syndrome. JAMA Cardiol. 2018, 3, 104–111. [Google Scholar] [CrossRef]
- Hemmert, K.C.; Sun, B.C. High-Sensitivity Cardiac Troponin Assay in Patients With Kidney Impairment: A Challenge to Clinical Implementation. JAMA Intern. Med. 2021, 181, 1239–1241. [Google Scholar] [CrossRef]
- Thygesen, K.; Alpert, J.S.; White, H.D. Universal definition of myocardial infarction. J. Am. Coll. Cardiol. 2007, 50, 2173–2195. [Google Scholar] [CrossRef]
- Gallacher, P.J.; Miller-Hodges, E.; Shah, A.S.V.; Anand, A.; Dhaun, N.; Mills, N.L. Use of High-Sensitivity Cardiac Troponin in Patients with Kidney Impairment: A Randomized Clinical Trial. JAMA Intern. Med. 2021, 181, 1237–1239. [Google Scholar] [CrossRef] [PubMed]
- Adewale, A.O.; Ahn, Y.H. Titin N2A Domain and Its Interactions at the Sarcomere. Int. J. Mol. Sci. 2021, 22, 7563. [Google Scholar] [CrossRef] [PubMed]
- LeWinter, M.M.; Granzier, H. Cardiac titin: A multifunctional giant. Circulation 2010, 121, 2137–2145. [Google Scholar] [CrossRef] [PubMed]
- Ali, M.A.; Cho, W.J.; Hudson, B.; Kassiri, Z.; Granzier, H.; Schulz, R. Titin is a target of matrix metalloproteinase-2: Implications in myocardial ischemia/reperfusion injury. Circulation 2010, 122, 2039–2047. [Google Scholar] [CrossRef] [PubMed]
- Rahim, M.A.A.; Rahim, Z.H.A.; Ahmad, W.A.W.; Bakri, M.M.; Ismail, M.D.; Hashim, O.H. Inverse changes in plasma tetranectin and titin levels in patients with type 2 diabetes mellitus: A potential predictor of acute myocardial infarction? Acta Pharmacol. Sin. 2018, 39, 1197–1207. [Google Scholar] [CrossRef] [PubMed]
- Bogomolovas, J.; Gasch, A.; Bajoras, V.; Karčiauskaitė, D.; Šerpytis, P.; Grabauskienė, V.; Labeit, D.; Labeit, S. Cardiac specific titin N2B exon is a novel sensitive serological marker for cardiac injury. Int. J. Cardiol. 2016, 212, 232–234. [Google Scholar] [CrossRef] [PubMed]
- Matsumura, K.; Shimizu, T.; Nonaka, I.; Mannen, T. Immunochemical study of connectin (titin) in neuromuscular diseases using a monoclonal antibody: Connectin is degraded extensively in Duchenne muscular dystrophy. J. Neurol. Sci. 1989, 93, 147–156. [Google Scholar] [CrossRef]
- Nagueh, S.F.; Shah, G.; Wu, Y.; Torre-Amione, G.; King, N.M.; Lahmers, S.; Witt, C.C.; Becker, K.; Labeit, S.; Granzier, H.L. Altered titin expression, myocardial stiffness, and left ventricular function in patients with dilated cardiomyopathy. Circulation 2004, 110, 155–162. [Google Scholar] [CrossRef]
- Vassiliadis, E.; Rasmussen, L.M.; Byrjalsen, I.; Larsen, D.V.; Chaturvedi, R.; Hosbond, S.; Saabye, L.; Diederichsen, A.C.P.; Genovese, F.; Duffin, K.L.; et al. Clinical evaluation of a matrix metalloproteinase-12 cleaved fragment of titin as a cardiovascular serological biomarker. J. Transl. Med. 2012, 6, 140. [Google Scholar] [CrossRef]
- Rouillon, J.; Zocevic, A.; Leger, T.; Garcia, C.; Camadro, J.M.; Udd, B.; Wong, B.; Servais, L.; Voit, T.; Svinartchouk, F. Proteomics profiling of urine reveals specific titin fragments as biomarkers of Duchenne muscular dystrophy. Neuromuscul. Disord. 2014, 24, 563–573. [Google Scholar] [CrossRef]
- Maruyama, N.; Asai, T.; Abe, C.; Inada, A.; Kawauchi, T.; Miyashita, K.; Maeda, M.; Matsuo, M.; Nabeshima, Y.I. Establishment of a highly sensitive sandwich ELISA for the N-terminal fragment of titin in urine. Sci. Rep. 2016, 6, 39375. [Google Scholar] [CrossRef] [PubMed]
- Awano, H.; Matsumoto, M.; Nagai, M.; Shirakawa, T.; Maruyama, N.; Iijima, K.; Nabeshima, Y.I.; Matsuo, M. Diagnostic and clinical significance of the titin fragment in urine of Duchenne muscular dystrophy patients. Clin. Chim. Acta 2018, 476, 111–116. [Google Scholar] [CrossRef] [PubMed]
- Matsuo, M.; Shirakawa, T.; Awano, H.; Nishio, H. Receiver operating curve analyses of urinary titin of healthy 3-y-old children may be a noninvasive screening method for Duchenne muscular dystrophy. Clin. Chim. Acta 2018, 486, 110–114. [Google Scholar] [CrossRef] [PubMed]
- Yamada, S.; Hashizume, A.; Hijikata, Y.; Ito, D.; Kishimoto, Y.; Iida, M.; Koike, H.; Hirakawa, A.; Katsuno, M. Ratio of urinary N-terminal titin fragment to urinary creatinine is a novel biomarker for amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 2021, 92, 1072–1079. [Google Scholar] [CrossRef]
- Yamaguchi, S.; Suzuki, K.; Kanda, K.; Okada, J. N-terminal fragments of titin in urine as a biomarker for eccentric exercise-induced muscle damage. J. Phys. Fit. Sports Med. 2020, 9, 21–29. [Google Scholar] [CrossRef]
- Kanda, K.; Sakuma, J.; Akimoto, T.; Kawakami, Y.; Suzuki, K. Detection of titin fragments in urine in response to exercise-induced muscle damage. PLoS ONE 2017, 12, e0181623. [Google Scholar] [CrossRef]
- Nakanishi, N.; Tsutsumi, R.; Hara, K.; Takashima, T.; Nakataki, E.; Itagaki, T.; Matsuo, M.; Oto, J.; Sakaue, H. Urinary Titin Is a Novel Biomarker for Muscle Atrophy in Nonsurgical Critically Ill Patients: A Two-Center, Prospective Observational Study. Crit. Care Med. 2020, 48, 1327–1333. [Google Scholar] [CrossRef]
- Kötter, S.; Kazmierowska, M.; Andresen, C.; Bottermann, K.; Grandoch, M.; Gorressen, S.; Heinen, A.; Moll, J.M.; Scheller, J.; Gödecke, A.; et al. Titin-Based Cardiac Myocyte Stiffening Contributes to Early Adaptive Ventricular Remodeling after Myocardial Infarction. Circ. Res. 2016, 119, 1017–1029. [Google Scholar] [CrossRef]
- Metter, E.J.; Lynch, N.; Conwit, R.; Lindle, R.; Tobin, J.; Hurley, B. Muscle quality and age: Cross-sectional and longitudinal comparisons. J. Gerontol. A Biol. Sci. Med. Sci. 1999, 54, B207–B218. [Google Scholar] [CrossRef]
- Shaw, S.C.; Dennison, E.M.; Cooper, C. Epidemiology of Sarcopenia: Determinants Throughout the Lifecourse. Calcif. Tissue Int. 2017, 101, 229–247. [Google Scholar] [CrossRef]
- Lopes, L.C.C.; Vaz-Gonçalves, L.; Schincaglia, R.M.; Gonzalez, M.C.; Prado, C.M.; de Oliveira, E.P.; Mota, J.F. Sex and population-specific cutoff values of muscle quality index: Results from NHANES 2011–2014. Clin. Nutr. 2022, 41, 1328–1334. [Google Scholar] [CrossRef]
- Dohi, T.; Maehara, A.; Brener, S.J.; Généreux, P.; Gershlick, A.H.; Mehran, R.; Gibson, C.M.; Mintz, G.S.; Stone, G.W. Utility of peak creatine kinase-MB measurements in predicting myocardial infarct size, left ventricular dysfunction, and outcome after first anterior wall acute myocardial infarction (from the INFUSE-AMI trial). Am. J. Cardiol. 2015, 115, 563–570. [Google Scholar] [CrossRef] [PubMed]
- Lindsey, J.B.; Kennedy, K.F.; Stolker, J.M.; Gilchrist, I.C.; Mukherjee, D.; Marso, S.P.; Pencina, M.J.; Kleiman, N.S.; Cohen, D.J. Prognostic implications of creatine kinase-MB elevation after percutaneous coronary intervention: Results from the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry. Circ. Cardiovasc. Interv. 2011, 4, 474–480. [Google Scholar] [CrossRef] [PubMed]
- Ioannidis, J.P.; Karvouni, E.; Katritsis, D.G. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J. Am. Coll. Cardiol. 2003, 42, 1406–1411. [Google Scholar] [CrossRef] [PubMed]
- Stone, G.W.; Mehran, R.; Dangas, G.; Lansky, A.J.; Kornowski, R.; Leon, M.B. Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: A device-specific analysis of 7147 patients. Circulation 2001, 104, 642–647. [Google Scholar] [CrossRef] [PubMed]
- Harrington, R.A.; Lincoff, A.M.; Califf, R.M.; Holmes, D.R., Jr.; Berdan, L.G.; O’Hanesian, M.A.; Keeler, G.P.; Garratt, K.N.; Ohman, E.M.; Mark, D.B.; et al. Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: Insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). J. Am. Coll. Cardiol. 1995, 25, 1693–1699. [Google Scholar] [CrossRef]
- Kugelmass, A.D.; Cohen, D.J.; Moscucci, M.; Piana, R.N.; Senerchia, C.; Kuntz, R.E.; Baim, D.S. Elevation of the creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting. Am. J. Cardiol. 1994, 74, 748–754. [Google Scholar] [CrossRef]
- Kong, T.Q.; Davidson, C.J.; Meyers, S.N.; Tauke, J.T.; Parker, M.A.; Bonow, R.O. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA 1997, 277, 461–466. [Google Scholar] [CrossRef]
- Mozos, I.; Jianu, D.; Gug, C.; Stoian, D. Links between High-Sensitivity C-Reactive Protein and Pulse Wave Analysis in Middle-Aged Patients with Hypertension and High Normal Blood Pressure. Dis. Markers 2019, 2019, 2568069. [Google Scholar] [CrossRef]
Median (IQR) unless Otherwise Noted | ||||
---|---|---|---|---|
All | Non-AMI | AMI | p-Value | |
(n = 83) | (n = 32) | (n = 51) | (Non-AMI vs. AMI) | |
Age (years), mean ± SD | 73.0 ± 12.1 | 76.1 ± 12.4 | 71.0 ± 11.6 | 0.063 |
Male sex, n (%) | 60 (72.3) | 22 (68.8) | 38 (74.5) | 0.568 |
BMI (kg/m2) | 22.8 (20.8–26.2) | 22.2 (20.2–26.0) | 23.6 (21.2–26.5) | 0.128 |
Comorbidities, n (%) | ||||
Cardiovascular diseases | 24 (29.6) | 18 (56.3) | 6 (12.2) | <0.001 |
Hypertension | 54 (66.7) | 21 (65.6) | 33 (67.3) | 0.872 |
Diabetes mellitus | 35 (43.2) | 10 (31.3) | 25 (51.0) | 0.079 |
Dyslipidemia | 29 (35.8) | 12 (37.5) | 17 (34.7) | 0.797 |
Renal failure | 11 (13.6) | 6 (18.8) | 5 (10.2) | 0.272 |
Former or current Smoker, n (%) | 40 (48.8) | 12 (37.5) | 28 (56.0) | 0.102 |
ECG: STEMI, n (%) | 54 (65.1) | 9 (28.1) | 45 (88.2) | <0.001 |
Chest pain, n (%) | 56 (67.5) | 18 (56.3) | 38 (74.5) | 0.084 |
Hospital discharge disposition, n (%) | ||||
Home | 66 (79.5) | 27 (84.4) | 39 (76.5) | |
Transfer to other facilities | 9 (10.8) | 4 (12.5) | 5 (9.8) | |
Deceased | 8 (9.6) | 1 (3.1) | 7 (13.7) | |
Time since symptom onset, n (%) | 0.683 | |||
>3 h | 34 (41.0) | 14 (43.8) | 20 (39.2) | |
≤3 h | 49 (59.0) | 18 (56.3) | 31 (60.8) | |
Heart rate (beats/min) | 73.0 (60.8–88.0) | 73.0 (62.0–87.0) | 73.0 (60.0–92.0) | 0.789 |
Systolic blood pressure (mmHg), mean ± SD | 138.1 ± 31.3 | 153.1 ± 27.8 | 129.4 ± 30.2 | <0.001 |
Diastolic blood pressure (mmHg), mean ± SD | 82.1 ± 21.4 | 86.5 ± 20.3 | 79.5 ± 21.8 | 0.158 |
SpO2 (%) | 98.0 (95.8–99.0) | 98.0 (97.0–99.0) | 97.0 (95.0–99.0) | 0.174 |
BNP (pg/mL) | 93.5 (22.3–235.5) | 152.7 (32.7–330.4) | 56.5 (19.8–127) | 0.027 |
BUN (mg/dL) | 17.8 (13.9–21.1) | 18.8 (13.5–20.8) | 17.5 (14.7–22.0) | 0.925 |
eGFR (mL/min/1.73 m2), mean ± SD | 62.3 ± 21.9 | 63.6 ± 22.5 | 61.5 ± 21.7 | 0.684 |
Serum Cre (mg/dL) | 0.9 (0.7–1.1) | 0.8 (0.6–1.1) | 0.9 (0.7–1.2) | 0.250 |
Serum Troponin I (pg/mL) | 156 (24–2,865) | 47 (7–245) | 254 (42–12,233) | 0.003 |
Serum CK (U/L) | 126 (81–306) | 95 (68–201) | 165 (98–520) | 0.003 |
Serum CK-MB (U/L) | 11.0 (4.1–22.0) | 6.0 (1.5–15.0) | 12.8 (7.0–33.0) | 0.007 |
Urinary Titin (pmol/mg Cr) | 5.58 (3.70–13.03) | 4.75 (3.67–11.70) | 6.35 (3.77–14.76) | 0.335 |
Wilcoxon Rank Sum Test | Median (IQR) | |
---|---|---|
Urinary Titin (pmol/mgCr) | p-Value | |
Sex | 0.531 | |
Male | 6.31 (3.87–12.94) | |
Femele | 4.91 (3.63–13.96) | |
Spearman’s rank correlation | ||
rs | p-value | |
Age | 0.138 | 0.213 |
BMI | 0.116 | 0.298 |
Systolic blood pressure | −0.020 | 0.862 |
Diastolic blood pressure | −0.057 | 0.613 |
SpO2 | −0.200 | 0.071 |
CK | 0.586 | <0.001 |
CK-MB | 0.280 | 0.010 |
Serum Hs-Troponin I | 0.402 | <0.001 |
BUN | 0.311 | 0.004 |
BNP | 0.460 | <0.001 |
eGFR | −0.201 | 0.068 |
β | p-Value | |
---|---|---|
Age | 0.019 | 0.878 |
CK (log) | 0.465 | <0.001 |
BNP (log) | 0.298 | 0.014 |
eGFR | −0.074 | 0.502 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Arase, M.; Nakanishi, N.; Tsutsumi, R.; Kawakami, A.; Arai, Y.; Sakaue, H.; Oto, J. The Utility of Urinary Titin to Diagnose and Predict the Prognosis of Acute Myocardial Infarction. Int. J. Mol. Sci. 2024, 25, 573. https://doi.org/10.3390/ijms25010573
Arase M, Nakanishi N, Tsutsumi R, Kawakami A, Arai Y, Sakaue H, Oto J. The Utility of Urinary Titin to Diagnose and Predict the Prognosis of Acute Myocardial Infarction. International Journal of Molecular Sciences. 2024; 25(1):573. https://doi.org/10.3390/ijms25010573
Chicago/Turabian StyleArase, Miharu, Nobuto Nakanishi, Rie Tsutsumi, Ayuka Kawakami, Yuta Arai, Hiroshi Sakaue, and Jun Oto. 2024. "The Utility of Urinary Titin to Diagnose and Predict the Prognosis of Acute Myocardial Infarction" International Journal of Molecular Sciences 25, no. 1: 573. https://doi.org/10.3390/ijms25010573